VERVE THERAPEUTICS INC. - COMMON STOCK

Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement

01 дек 2023 15:00:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

28 ноя 2023 21:37:08 Источник Nasdaq GlobeNewswire

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

28 ноя 2023 15:01:51 Источник Nasdaq GlobeNewswire

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

07 ноя 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

31 окт 2023 05:01:28 Источник Nasdaq GlobeNewswire

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

23 окт 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023

26 сен 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

21 сен 2023 15:05:00 Источник Nasdaq GlobeNewswire

Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

18 сен 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results

10 авг 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference

03 авг 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease

15 июн 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

01 июн 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day

23 май 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results

15 май 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference

09 май 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

27 мар 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

03 мар 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

02 мар 2023 05:30:00 Источник Nasdaq GlobeNewswire

Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia

14 фев 2023 05:30:00 Источник Nasdaq GlobeNewswire